Myeloma Paper of the Day, June 29th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Real-world analysis of renally impaired myeloma patients finds bortez-dex (Bortezomib – Dexamethasone) is most prevalent 1L regimen, shorter PFS (Progression-Free Survival) and OS (Overall Survival), higher healthcare resource utilization and higher clinical and economic burden vs. general myeloma population.”
Source: Robert Orlowski/X
Authors: Parameswaran Hari, Dominick Latremouille-Viau, Peggy Lin, Annie Guerin and Medha Sasane.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
